Sedrofen

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sedrofen

Quick Facts: Sedrofen (Cefadroxil)

Property Description
Active ingredient Cefadroxil (Monohydrate)
Form Capsule, Tablet, Oral Suspension
Pharmacological class Antibiotic
Common use Clearing bacterial infections
Origin Semisynthetic (Beta-lactam)

What Type of Medicine is Sedrofen?

Sedrofen is a prescription-only medicine whose therapeutic activity is driven by the active ingredient Cefadroxil. It is classified as an Antibiotic, belonging specifically to the cephalosporin family of drugs. Cefadroxil is further specified as a first-generation cephalosporin, a classification derived from its chemical structure and established spectrum of activity. The structure of Cefadroxil is clinically recognized as a semisynthetic beta-lactam antibiotic capable of fighting infection.

The medicine is intended for oral administration and is typically provided as a single active ingredient product in multiple dosage forms, including capsules, tablets, or a powder used to create an oral suspension. The availability of the pediatric oral suspension form makes Cefadroxil a versatile choice for a broad patient group.

Composition and General Purpose of Cefadroxil

The core purpose of Cefadroxil is to combat bacterial infections through a definitive bactericidal effect. This function is achieved by interfering with the vital process of bacterial cell wall synthesis, meaning the medication actively destroys susceptible bacteria rather than simply stopping their growth.

By disrupting the formation of the cell's rigid structure, the medicine effectively causes the bacterial cell to break down and die, providing the general therapeutic benefit of clearing bacterial proliferation. Cephalosporin antibiotics, like Cefadroxil, are well-established for their cell-killing mechanisms against susceptible organisms, confirming its action is geared toward eliminating the root cause of the bacterial presence.

Regulatory References

  1. Cefadroxil FDA Label (DailyMed/NIH)
  2. Cefadroxil Summary of Product Characteristics (SmPC)

What side effects are possible with Sedrofen?

Possible Side Effects and Safety Information

The safety profile of Sedrofen, as documented in authoritative regulatory sources, details potential adverse reactions categorized by frequency and affected body systems.

Commonly Reported Side Effects

The most frequently reported adverse reactions affect the Gastrointestinal system and the Skin and subcutaneous tissue. Common events include diarrhea, nausea, vomiting, stomach pain, pruritus (itching), and rash/allergic exanthema.

Serious and Clinically Significant Adverse Reactions

The following are recognized as rare but potentially serious events and are critical components of the official safety profile:

  • Hypersensitivity Reactions: Severe, acute allergic responses, including anaphylactic shock and serious skin conditions such as Stevens-Johnson syndrome and Toxic Epidermal Necrolysis, have been reported. Cross-sensitivity with other beta-lactam antibiotics (e.g., penicillins) has been clearly documented.
  • Gastrointestinal Complications: The development of Clostridioides difficile-associated diarrhea (CDAD), which can range in severity from mild diarrhea to fatal pseudomembranous colitis, is a documented risk associated with nearly all antibacterial agents, including Sedrofen.
  • Organ and Blood Disorders: Rare cases of hepatic dysfunction (e.g., transient elevation of liver enzymes) and renal dysfunction (e.g., interstitial nephritis) are documented. Certain serious blood and lymphatic system disorders, such as agranulocytosis and thrombocytopenia, have been reported, particularly with prolonged use.

Safety Restrictions and Population Considerations

Sedrofen is formally contraindicated in individuals with known hypersensitivity to the cephalosporin class of antibiotics. Caution is required in patients with a history of gastrointestinal disease, particularly colitis. The drug should also be used with caution in the presence of markedly impaired renal function (creatinine clearance rate less than 50 mL/min/1.73 m^2), as this may necessitate careful monitoring and potential dose adjustment. Prolonged use carries the risk of superinfection due to the overgrowth of non-susceptible organisms. The occurrence of certain neurological symptoms has been noted with high doses in cases of impaired kidney function.

Overdose and Emergency Response

An overdose of Sedrofen requires immediate medical attention, as it can lead to severe and life-threatening symptoms. The official regulatory documents identify specific critical clinical manifestations that necessitate urgent emergency intervention.

When to Seek Emergency Help

If any of the following serious signs are observed, call emergency services (such as 911) immediately:

  • Collapse or sudden loss of physical support.
  • Seizure or convulsions.
  • Trouble breathing or other signs of respiratory distress.
  • Inability to be awakened or an unarousable state (loss of consciousness).

These symptoms indicate a severe progression of overdose affecting the central nervous and respiratory systems. Immediate emergency response is required to manage these conditions.

General Overdose Response

For a suspected overdose where the severe symptoms listed above are not yet present, it is required to contact a poison control helpline (such as 1-800-222-1222) for expert guidance on next steps. Do not wait for symptoms to worsen if an overdose is suspected. The promptness of calling for help can be vital in managing the consequences of excessive exposure.

Therapeutic Uses of Sedrofen

What Sedrofen Treats: Main Uses and Benefits

Sedrofen (Cefadroxil) is commonly used to manage symptoms associated with bacterial infections and is applied in addressing conditions associated with acute or disruptive episodes. This medication is applied across therapeutic domains including the skin, throat, tonsils, and urinary tract.

It is relevant in clinical settings applied in addressing conditions like uncomplicated cellulitis, impetigo, pharyngitis, tonsillitis, and cystitis. Its use is relevant for managing symptoms related to inflammatory or irritative states, such as localized pain, redness, and swelling, or severe sore throat and painful urination.

Supportive Use and Infection Prevention

Sedrofen is applied in contexts where additional symptomatic support is needed, often considered relevant for patients with penicillin allergies. It is also relevant in situations requiring short-term symptomatic assistance by assisting with the management of a specific infection (prophylaxis) in at-risk patients prior to certain procedures. This supportive role assists with maintaining functional stability during periods of heightened physiological stress.


Quick Fact: Symptom Axes Addressed
Symptom Axes Addressed: Pain, Inflammation, and Fever
Conditions Managed: Acute Infections of the Skin/Throat/Urinary Tract
Patient Benefit: Contributes to easing the overall symptom load during symptomatic periods

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility for Sedrofen: Official Regulatory Information

The eligibility profile for Sedrofen, based on official regulatory documents (such as FDA and EMA), defines clear restrictions and absolute contraindications for its use.

Contraindications (Must Not Use):

  • Hypersensitivity: The medicine is strictly contraindicated for any individual with a confirmed allergy to Sedrofen itself, to the cephalosporin class of antibiotics, or a history of severe immediate allergic reactions to penicillins or other beta-lactam drugs due to the risk of cross-reactivity.

Restricted and Conditional Use:

Population/Condition Eligibility Status
Renal Impairment Requires caution; dosage adjustment is necessary based on the degree of kidney function to prevent drug accumulation.
Pregnancy Use is generally not recommended or conditional; use is permitted only if the prescriber determines the clear benefit outweighs the potential risk to the fetus.
Lactation Use with caution; the drug is excreted into breast milk, and some labels advise monitoring the infant or discontinuing breastfeeding.
Pediatric Use Use in infants and very young children may be not recommended or lack established safety data, depending on the specific age and formulation.

These constraints ensure that only patients who pass the mandatory allergy screening and meet the physiological criteria defined in the official labeling are considered eligible for treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the officially documented interaction patterns for Sedrofen (Cefadroxil) as defined by government regulatory agencies.

Pharmacokinetic and Exposure Interactions

The regulatory profile documents a pharmacokinetic interaction with Probenecid, an agent that inhibits renal tubular secretion. Co-administration of Probenecid reduces the renal elimination of Cefadroxil, which results in increased and prolonged plasma concentrations of the antibiotic. No specific interaction involving the Cytochrome P450 (CYP) enzyme system is officially documented.

Pharmacodynamic and Toxicity Interactions

Interaction reports indicate potential for enhanced effects when Sedrofen is used alongside other medicines. Co-administration with Aminoglycoside antibiotics or Loop Diuretics (such as Furosemide) may lead to an enhanced nephrotoxic effect. Additionally, the medicine may potentiate the anticoagulant effect of Vitamin K Antagonists (e.g., Warfarin), which increases the overall risk of bleeding.

Procedural and Administration Constraints

The use of Cefadroxil has been associated with a potential positive result on the Direct Coombs’ test, a procedural constraint that should be considered during laboratory testing. For administration, the official documents state that Sedrofen may be taken with or without food; administration with food is noted as a condition that may improve gastrointestinal tolerability.

Population-Specific Considerations

In patients with markedly impaired renal function, slower clearance leads to increased systemic exposure to Cefadroxil. This condition requires caution, as the heightened exposure increases the potential for concentration-dependent adverse effects.

Mechanism of Action

How Sedrofen Works

Sedrofen initiates a targeted influence on specific cellular signaling systems to modulate the output of dysregulated pathways. Its action focuses strictly on modifying key molecular steps within defined neuro-humoral networks.


Targeting the R1a Receptor System

Sedrofen acts as a competitive antagonist primarily on the R1a receptor. This action involves occupying the receptor binding site, which directly blocks the activity of the body’s endogenous signaling molecule. This selective modulation of the R1a receptor system leads to a reduction in downstream signal propagation.


Modulating Signal Transduction Cascades

The blockage of the R1a receptor directly interferes with the M1 signal transduction pathway. By suppressing the initial receptor activation, Sedrofen prevents the subsequent chain of intracellular molecular events—the signal cascade—from escalating. This mechanism results in the suppression of signaling activity within affected pathways, generating a modified physiological output.


Resulting Mechanistic Influence

The combined mechanistic action—receptor antagonism followed by pathway interference—results in the limiting of signal amplitude within specific physiological pathways. This leads to a reduction in pathway output within the affected systems, resulting in the characteristic mechanistic influence of the compound.

Dosage and Administration Information

Administration and Dosing Schedule

Sedrofen (Cefadroxil) is administered exclusively by the oral route, available in capsule, tablet, and reconstituted oral suspension forms. For the majority of adult infections, the standard total daily dose ranges from 1 g to 2 g, administered either once daily or in two divided doses. The full course of therapy must be completed to prevent bacterial resistance; specifically, treatment for infections caused by Group A streptococci requires a minimum duration of 10 consecutive days.


Contextual Usage and Preparation

The medication may be taken with or without food, as administration with food may help mitigate potential gastrointestinal discomfort. For the liquid oral suspension, the product must be shaken well before each use and measured with a calibrated device. Certain high-dose uses, such as endocarditis prophylaxis, mandate a single 2 g dose administered precisely one hour prior to the procedure.


Population and Procedural Adjustments

Dose adjustments are required for adults with renal impairment (creatinine clearance leq 50 mL/min/1.73 m^2), necessitating a modified dosing interval based on the degree of impairment. If a dose is missed, it should be taken as soon as remembered unless it is near the time for the next scheduled dose; in this scenario, the missed dose must be skipped, and the dose should not be doubled.

Recent Clinical Evidence

Research Evidence for Sedrofen (Cefadroxil)


Evidence for Use in Urinary Tract Infections (UTI)

Sedrofen was studied for its use in uncomplicated lower urinary tract infections (UTIs) caused by certain susceptible bacteria. Research was often structured as Randomized Controlled Trials (RCTs) where Cefadroxil was compared against other established antibiotic therapies. Studies monitored key outcomes related to the bacteriological cure rate (elimination of the pathogen) and the clinical cure rate (evaluation of change in outcomes linked to inflammatory states).

Findings describe patterns observed in the studies where measurements of pathogen clearance were reported for susceptible organisms. Studies monitored whether the resolution of patient-reported outcomes was associated with the measured microbiological outcomes. The results apply only to the populations studied, and data are still emerging for its evaluation in more complicated or severe UTIs.

Evidence for Use in Skin and Skin Structure Infections

The clinical evaluation for skin infections like cellulitis and impetigo primarily used comparative RCTs. Research examined diverse populations, including both adults and children, presenting with uncomplicated infections. Primary endpoints measured included the Clinical Cure or Clinical Improvement rate (monitoring change in symptoms like redness and swelling) and the Pathogen Eradication Rate.

Studies report how symptoms evolved in the observed populations, documenting measurements of clinical cure rates when the infections were caused by susceptible Staphylococci and Streptococci species. Research highlights patterns observed during the study period, with data showing patterns related to pathogen clearance. Data for certain groups, such as patients with significant comorbidities, remain insufficient.

What is Still Uncertain About Sedrofen Research

Research exploring short-term symptom changes for pharyngitis and tonsillitis is noted in regulatory documents as lacking data to confirm its role in the prevention of long-term complications like rheumatic fever. The duration of follow-up in primary clinical trials was typically short-term; consequently, long-term effects are not fully established beyond the immediate post-treatment follow-up period. Comparative evidence is lacking for many modern treatment scenarios.

Key Studies & References

  1. Short- vs. Long-Course Antibiotic Treatment for Acute Streptococcal Pharyngitis: Systematic Review and Meta-Analysis of RCTs
  2. Cephalosporins can be prescribed safely for penicillin-allergic patients (Cross-reactivity review)
  3. Evaluation of the effect of topical cefadroxil on bacterial load of pathogenic staphylococci... comparative study (Example RCT for SSSI)

Frequently Asked Questions (FAQ)

Common questions about Sedrofen (FAQ)

Q: How quickly does Sedrofen start to work?

A: Sedrofen is classified as a medicine that is rapidly absorbed after oral administration. According to official product information, concentrations of the drug in the blood generally reach their peak within 1.5 to 2 hours following a dose.

Q: How long does the effect of one Sedrofen dose usually last?

A: The half-life of Sedrofen (Cefadroxil) is approximately 1 to 2 hours in adults who have normal kidney function. Official pharmacological data indicates that more than 90% of the active medicine is usually cleared from the body through the urine within 24 hours of dosing.

Q: What if I forget to take my Sedrofen dose?

A: If a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose must be skipped. Official guidance specifies that the dose should not be doubled to compensate for the one that was forgotten.

Q: Are there any foods or drinks I should avoid while on Sedrofen?

A: Official drug documents do not list specific foods or drinks that must be avoided while taking Sedrofen. The medicine can be taken with or without food. Some people find that taking it with food helps to reduce potential gastrointestinal discomfort.

Q: Does Sedrofen interact with common supplements like Vitamin D or Omega-3s?

A: Regulatory documents list specific drug-to-drug interactions for Sedrofen. There is no official warning or documented interaction concerning common over-the-counter supplements such as Vitamin D or Omega-3 fatty acids.

Q: Can people with mild kidney issues take Sedrofen?

A: Sedrofen requires caution when used by individuals with impaired kidney function. The dose must be adjusted for moderate to severe impairment, which is defined as a creatinine clearance of less than or equal to 50 mL/min/1.73 m^2. Monitoring of kidney function may be necessary during treatment.

Q: Are there common drug classes that interact badly with Sedrofen?

A: Yes, official information documents several important drug interactions. These include a pharmacokinetic interaction with Probenecid, which increases the amount of Sedrofen in the body. Additionally, there is a potential for enhanced nephrotoxic effects when used with Aminoglycoside antibiotics and certain Loop Diuretics.

Q: Are there any long-term side effects associated with Sedrofen use?

A: For all antibacterial agents, including Sedrofen, prolonged use carries a risk of developing a superinfection due to the overgrowth of non-susceptible organisms. Official clinical trials typically have a short follow-up duration, meaning the long-term effects beyond the immediate post-treatment period are not fully established.

Q: What should I do if a side effect from Sedrofen feels severe?

A: Official safety information documents rare but serious adverse reactions, such as anaphylactic shock or severe diarrhea (Clostridioides difficile-associated diarrhea). If symptoms of a severe side effect or a serious allergic reaction occur (e.g., trouble breathing or swelling), immediate medical attention should be sought.

Q: What are the ingredients in Sedrofen besides the active component?

A: The active ingredient in this medicine is Cefadroxil (as monohydrate). The official drug label contains a full list of all inactive ingredients, or excipients, used in the final formulation. These inactive ingredients can vary depending on the specific dosage form and the manufacturer.

Q: Are there warnings about driving or operating machinery while on Sedrofen?

A: Some official labeling advises that caution should be used when driving or operating machinery. This is because Sedrofen has been associated with central nervous system side effects in some individuals, including dizziness, nervousness, sleeplessness, and general fatigue.

Q: Does Sedrofen cause weight gain or loss?

A: Regulatory documents list unusual weight loss as a rare side effect that has been reported during use of Sedrofen. Neither weight gain nor weight loss are included among the most common adverse reactions listed in the official safety profile.

Q: What happens if I stop taking Sedrofen suddenly?

A: The full course of therapy must be completed as prescribed to prevent the development of bacterial resistance. Stopping therapy too early may prevent the clearance of the infection and can lead to the re-emergence of the infection.

Q: Does Sedrofen affect my sleep schedule?

A: Adverse reaction reports include neurological effects, such as nervousness and sleeplessness (insomnia), as possible effects of Sedrofen. These effects are generally not common.

Q: What are the signs that Sedrofen might not be working for me?

A: Clinical studies define successful treatment as achieving a clinical cure, which is the resolution of symptoms, and pathogen eradication. Signs that the medicine may not be working would include the failure of symptoms to improve, or a noticeable worsening of the signs of infection.

Q: Can Sedrofen be used to treat migraines?

A: No. According to the FDA and EMA, Sedrofen is officially approved only for the treatment of specific bacterial infections, such as those affecting the skin, tonsils/pharynx, and urinary tract. It is not indicated or approved for the treatment of migraines.

Q: Is Sedrofen safe to take during the summer heat?

A: The tablets and capsules of Sedrofen must be stored at controlled room temperature and kept away from excess heat. While not a primary warning, severe skin reactions are possible with this class of drug, and these reactions may be potentially affected by intense sun exposure.

Q: Do many people experience a rash when taking Sedrofen?

A: Yes, regulatory documents list rash and allergic exanthema (a general skin eruption) as a commonly reported side effect of Sedrofen. These skin reactions typically resolve once the medication is stopped.

Q: Can men and women use Sedrofen for the same conditions?

A: Yes. The official indications—the specific conditions for which Sedrofen is approved, such as UTIs and skin infections—apply equally to both the adult male and adult female populations.

Q: Is the maximum daily dose for Sedrofen generally safe for most people?

A: The maximum approved daily dose is based on data to balance therapeutic benefit with risk for the general population. However, caution is required, and doses must be adjusted for specific groups, particularly those with impaired kidney function or certain pre-existing gastrointestinal conditions.

Q: Will Sedrofen make me feel tired or lethargic?

A: Adverse reaction reports include general fatigue and unusual tiredness or weakness as possible side effects of Sedrofen. These effects are not typically categorized among the most common adverse reactions.

Q: Does Sedrofen have a generic version available?

A: Yes. The active ingredient in Sedrofen, Cefadroxil, is a widely used compound and is available in generic form from various manufacturers.

Q: What is the shelf life of Sedrofen after the bottle is opened?

A: For the dry capsules and tablets, stability is generally maintained until the expiration date printed on the bottle, provided they are stored properly. However, the reconstituted liquid suspension must be kept refrigerated and must be discarded 14 days after it is prepared.

Q: Is the Sedrofen formulation (tablet vs. capsule) important?

A: Sedrofen is available in various forms including capsules, tablets, and a liquid suspension. All formulations deliver the same active ingredient, Cefadroxil. The choice of form may be based on patient preference or the prescribed total daily dose.

Q: Is it okay to take Sedrofen if I occasionally drink alcohol?

A: Official drug documents for Sedrofen (Cefadroxil) do not list a specific interaction or contraindication with the use of alcohol. However, it is important to note that consuming alcohol may potentially worsen any gastrointestinal side effects that are experienced while taking the medicine.

Q: Can Sedrofen make me more sensitive to the sun?

A: While not listed as a primary warning, Sedrofen belongs to a class of antibiotics that has been linked to severe skin reactions. These types of reactions may potentially be triggered or worsened by sun exposure, so caution is advised.

How should Sedrofen be stored and disposed of?

How to Store and Dispose of Sedrofen (Cefadroxil)

Official storage conditions for Sedrofen differ based on the form of the medicine, and all forms must be kept out of the reach of children.

Dosage Form Required Storage Condition Stability/Handling Rules
Capsules/Tablets (Dry) Store at controlled room temperature (20 C to 25 C) in the original, tightly closed container. Keep away from heat and moisture. Do not freeze.
Oral Suspension (Liquid) Store the reconstituted suspension in the refrigerator (2 C to 8 C). Must be discarded after 14 days; do not freeze the liquid.

Disposal must follow local guidelines; unused or expired Sedrofen should generally be disposed of through a drug take-back program. The medicine should not be flushed down a sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sedrofen found in:

A-Z Index: